Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;21(4):e103-e109.
doi: 10.1016/S1473-3099(20)30923-3. Epub 2020 Dec 8.

The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials

Jerome Amir Singh  1 , Ross E G Upshur  2
Affiliations
Review

The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials

Jerome Amir Singh et al. Lancet Infect Dis. 2021 Apr.

Abstract

An efficacious COVID-19 vaccine is currently the world's leading research priority. Several nations have indicated that if there is a compelling case for use of a vaccine before it is licensed, they would be prepared to authorise its emergency use or conditional approval on public health grounds. As of Dec 1, 2020, several developers of leading COVID-19 candidate vaccines have indicated that they have applied, or intend to apply, for emergency authorisation for their vaccines. Should candidate vaccines attain emergency use designation and be programmatically deployed before their phase 3 trials conclude, such a strategy could have far reaching consequences for COVID-19 vaccine research and the effective control of the COVID-19 pandemic. These issues merit careful consideration.

PubMed Disclaimer

References

    1. Vekemans J, Crofts J, Baker CJ, et al. The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. Vaccine. 2019;37:3190–3198. - PMC - PubMed
    1. Pfizer Pfizer and Biontech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. Nov 18, 2020. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-an...
    1. Gamaleya Research Institute of Epidemiology and Microbiology. Russian Direct Investment Fund The first interim data analysis of the Sputnik V vaccine against COVID-19 phase III clinical trials in the Russian Federation demonstrated 92% efficacy. Nov 11, 2020. https://sputnikvaccine.com/newsroom/pressreleases/the-first-interim-data...
    1. Moderna Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study. Nov 16, 2020. https://investors.modernatx.com/node/10316/pdf
    1. AstraZeneca AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. Nov 23, 2020. https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr....

Substances